Totally agree that the data once released will be the catalyst for Leron. As an investor, I am glad that they are taking time to validate and re-validate the data before it is released to the medical community. Data that is thought valid and has to be corrected creates doubt that will impact share price much more than a week or two of additional analysis. I thought the call was good and the hints on the outcome were there if you were listening.

Another observation is the gentleman that hosted the call and logistics of the call were 100% improved from recent conference calls. He did a good job.

IMHO